We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Canadian Regulator Reviewing Prexige Safety
Canadian Regulator Reviewing Prexige Safety
August 17, 2007
Health Canada announced it is reviewing new safety information on serious liver adverse events in patients using Novartis’ Cox-2 inhibitor Prexige, a treatment for osteoarthritis.